In 1998, Cardinal Health acquired R.P. Scherer Corporation of Troy, Michigan for $2.2 billion; it was founded by Robert Pauli Scherer to commercialize his innovation of softgel encapsulation using the rotary die production process.[4][5][6]
In 1999, Cardinal Health acquired Automatic Liquid Packaging of Woodstock, Illinois, thereby entering the sterile product market with blow fill seal technology.[7]
In January 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oral modified-release dosage form development and manufacturing, for $40 million.[8] In April 2002, Cardinal Health acquired Magellan Laboratories, a company that specialized in product development expertise.[9]
In October 2003, Cardinal Health acquired Gala Biotech of Madison, Wisconsin for $15.5 million.[10]
It also acquired Intercare Group of the UK for $530 million, broadening its global capabilities in Europe.[11]
2007–2019
In April 2007, the pharmaceutical technologies and services segment of Cardinal Health was acquired by affiliates of the The Blackstone Group and re-branded as Catalent Pharma Solutions.[12][13]
In February 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[14][15] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[6][16]
In March 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology, a China-based company, and Relthy Laboratories in Brazil.[17][18]
In November 2014, Catalent acquired Micron Technologies, a provider of particle size engineering technologies, expanding its portfolio of drug delivery technologies.[21]
In September 2016, Catalent acquired Pharmatek Laboratories to add spray drying capabilities.[22][23]
In October 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,[24]
In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, expanding its biologic manufacturing.[25]
In July 2018, Catalent acquired Juniper Pharmaceuticals for $133 million.[26]
In March 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to facilities in Swindon, UK; and a custom suite for commercial equipment.[27]
In September 2018, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.[28]
In May 2019, Catalent acquired Paragon Bioservices for $1.2 billion to expand its gene-therapy manufacturing capabilities.[29][30] By October 2019, Paragon's employee count doubled since the April acquisition.[31]
2020–present
In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[32]
In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million, to expand into cell therapy development.[33][34]
In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,[35]AstraZeneca,[36] and Moderna[37] to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccines.[38][39] In the partnership with AstraZeneca, Catalent provided manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.[40] Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's facility in St. Petersburg, Florida.[41]
In August 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics.[42] That month, Catalent also acquired Bettera Holdings, a nutritional supplement company, for $1 billion to provide capability to manufacture vitamins, minerals and supplements in gummy form.[43]
In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in Shiga, Japan.[44]
In December 2024, Novo Holdings A/S acquired Catalent for $16.5billion. As part of the transaction, Novo Nordisk acquired three manufacturing facilities from parent Novo Holdings for $11billion to scale up production to meet the demand of Wegovy and Ozempic.[49][50]
